CRISPR/Cas9 Genome Editing for Tissue-Specific In Vivo Targeting: Nanomaterials and Translational Perspective

Overview

Journal Adv Sci (Weinh)

Specialty Biomedical Engineering

Date 2023 May 11

PMID 37166046

Authors

Deepak Kumar Sahel

Lalitkumar K Vora

Aishwarya Saraswat

Saurabh Sharma

Jasmin Monpara

Anisha A DSouza

Deepakkumar Mishra

Kamatham Pushpa Tryphena

Satoru Kawakita

Shahid Khan

Mohd Azhar

Dharmendra Kumar Khatri

Ketan Patel

Raghu Raj Singh Thakur

Affiliations

Soon will be listed here.

Abstract

Clustered randomly interspaced short palindromic repeats (CRISPRs) and its associated endonuclease protein, i.e., Cas9, have been discovered as an immune system in bacteria and archaea; nevertheless, they are now being adopted as mainstream biotechnological/molecular scissors that can modulate ample genetic and nongenetic diseases via insertion/deletion, epigenome editing, messenger RNA editing, CRISPR interference, etc. Many Food and Drug Administration-approved and ongoing clinical trials on CRISPR adopt ex vivo strategies, wherein the gene editing is performed ex vivo, followed by reimplantation to the patients. However, the in vivo delivery of the CRISPR components is still under preclinical surveillance. This review has summarized the nonviral nanodelivery strategies for gene editing using CRISPR/Cas9 and its recent advancements, strategic points of view, challenges, and future aspects for tissue-specific in vivo delivery of CRISPR/Cas9 components using nanomaterials.

Citing Articles

From Bench to Bedside: Translating Cellular Rejuvenation Therapies into Clinical Applications.

Saliev T, Singh P Cells. 2025; 13(24.

PMID: 39768144 PMC: 11674796. DOI: 10.3390/cells13242052.

Nanoparticle-Based Approaches in the Diagnosis and Treatment of Brain Tumors.

Pourmasoumi P, Banihashemian S, Zamani F, Rasouli-Nia A, Mehrabani D, Karimi-Busheri F J Clin Med. 2024; 13(23).

PMID: 39685907 PMC: 11642644. DOI: 10.3390/jcm13237449.

Reduced circulating CD63 extracellular vesicle levels associate with atherosclerosis in hypercholesterolaemic mice and humans.

Kestecher B, Nemeth K, Ghosal S, Sayour N, Gergely T, Bodnar B Cardiovasc Diabetol. 2024; 23(1):368.

PMID: 39420340 PMC: 11487797. DOI: 10.1186/s12933-024-02459-w.

Assessment of CRISPRa-mediated overexpression in an Parkinson's disease model.

Guzman-Sastoque P, Sotelo S, Esmeral N, Albarracin S, Sutachan J, Reyes L Front Bioeng Biotechnol. 2024; 12:1420183.

PMID: 39175618 PMC: 11338903. DOI: 10.3389/fbioe.2024.1420183.

Nanomaterials-assisted gene editing and synthetic biology for optimizing the treatment of pulmonary diseases.

Lei L, Pan W, Shou X, Shao Y, Ye S, Zhang J J Nanobiotechnology. 2024; 22(1):343.

PMID: 38890749 PMC: 11186260. DOI: 10.1186/s12951-024-02627-w.

References

Liu T, Jiang G, Song G, Zhu J, Yang Y . Fabrication of separable microneedles with phase change coating for NIR-triggered transdermal delivery of metformin on diabetic rats. Biomed Microdevices. 2020; 22(1):12. DOI: 10.1007/s10544-019-0468-8. View

Liu W, Li L, Jiang J, Wu M, Lin P . Applications and challenges of CRISPR-Cas gene-editing to disease treatment in clinics. Precis Clin Med. 2021; 4(3):179-191. PMC: 8444435. DOI: 10.1093/pcmedi/pbab014. View

Hattori Y, Suzuki S, Kawakami S, Yamashita F, Hashida M . The role of dioleoylphosphatidylethanolamine (DOPE) in targeted gene delivery with mannosylated cationic liposomes via intravenous route. J Control Release. 2005; 108(2-3):484-95. DOI: 10.1016/j.jconrel.2005.08.012. View

Yoshioka T, Yoshida S, Kurosaki T, Teshima M, Nishida K, Nakamura J . Cationic liposomes-mediated plasmid DNA delivery in murine hepatitis induced by carbon tetrachloride. J Liposome Res. 2009; 19(2):141-7. DOI: 10.1080/08982100802666514. View

Sankaran V, Menne T, Xu J, Akie T, Lettre G, Van Handel B . Human fetal hemoglobin expression is regulated by the developmental stage-specific repressor BCL11A. Science. 2008; 322(5909):1839-42. DOI: 10.1126/science.1165409. View

Di J, Gao X, Du Y, Zhang H, Gao J, Zheng A . Size, shape, charge and "stealthy" surface: Carrier properties affect the drug circulation time . Asian J Pharm Sci. 2021; 16(4):444-458. PMC: 8520042. DOI: 10.1016/j.ajps.2020.07.005. View

Hasanzadeh A, Radmanesh F, Kiani J, Bayandori M, Fatahi Y, Aref A . Photoluminescent functionalized carbon dots for CRISPR delivery: synthesis, optimization and cellular investigation. Nanotechnology. 2019; 30(13):135101. DOI: 10.1088/1361-6528/aafbf9. View

Sansbury B, Wagner A, Nitzan E, Tarcic G, Kmiec E . CRISPR-Directed Gene Editing of Plasmid DNA Catalyzed by Cpf1 (Cas12a) Nuclease and a Mammalian Cell-Free Extract. CRISPR J. 2019; 1(2):191-202. PMC: 6345151. DOI: 10.1089/crispr.2018.0006. View

Luther D, Lee Y, Nagaraj H, Scaletti F, Rotello V . Delivery approaches for CRISPR/Cas9 therapeutics in vivo: advances and challenges. Expert Opin Drug Deliv. 2018; 15(9):905-913. PMC: 6295289. DOI: 10.1080/17425247.2018.1517746. View

10.

Kusumoto K, Akita H, Santiwarangkool S, Harashima H . Advantages of ethanol dilution method for preparing GALA-modified liposomal siRNA carriers on the in vivo gene knockdown efficiency in pulmonary endothelium. Int J Pharm. 2014; 473(1-2):144-7. DOI: 10.1016/j.ijpharm.2014.07.007. View

11.

Maruggi G, Zhang C, Li J, Ulmer J, Yu D . mRNA as a Transformative Technology for Vaccine Development to Control Infectious Diseases. Mol Ther. 2019; 27(4):757-772. PMC: 6453507. DOI: 10.1016/j.ymthe.2019.01.020. View

12.

Tzeng S, Green J . Polymeric Nucleic Acid Delivery for Immunoengineering. Curr Opin Biomed Eng. 2019; 7:42-50. PMC: 6516536. DOI: 10.1016/j.cobme.2018.09.005. View

13.

Shirane D, Tanaka H, Nakai Y, Yoshioka H, Akita H . Development of an Alcohol Dilution-Lyophilization Method for Preparing Lipid Nanoparticles Containing Encapsulated siRNA. Biol Pharm Bull. 2018; 41(8):1291-1294. DOI: 10.1248/bpb.b18-00208. View

14.

Chen G, Abdeen A, Wang Y, Shahi P, Robertson S, Xie R . A biodegradable nanocapsule delivers a Cas9 ribonucleoprotein complex for in vivo genome editing. Nat Nanotechnol. 2019; 14(10):974-980. PMC: 6778035. DOI: 10.1038/s41565-019-0539-2. View

15.

Foroozandeh P, Abdul Aziz A . Insight into Cellular Uptake and Intracellular Trafficking of Nanoparticles. Nanoscale Res Lett. 2018; 13(1):339. PMC: 6202307. DOI: 10.1186/s11671-018-2728-6. View

16.

Makowski E, Wu L, Gupta P, Tessier P . Discovery-stage identification of drug-like antibodies using emerging experimental and computational methods. MAbs. 2021; 13(1):1895540. PMC: 8346245. DOI: 10.1080/19420862.2021.1895540. View

17.

Mellott A, Forrest M, Detamore M . Physical non-viral gene delivery methods for tissue engineering. Ann Biomed Eng. 2012; 41(3):446-68. PMC: 5102682. DOI: 10.1007/s10439-012-0678-1. View

18.

Xu J, Peng C, Sankaran V, Shao Z, Esrick E, Chong B . Correction of sickle cell disease in adult mice by interference with fetal hemoglobin silencing. Science. 2011; 334(6058):993-6. PMC: 3746545. DOI: 10.1126/science.1211053. View

19.

Lin Y, Wu J, Gu W, Huang Y, Tong Z, Huang L . Exosome-Liposome Hybrid Nanoparticles Deliver CRISPR/Cas9 System in MSCs. Adv Sci (Weinh). 2018; 5(4):1700611. PMC: 5908366. DOI: 10.1002/advs.201700611. View

20.

Grieger J, Soltys S, Samulski R . Production of Recombinant Adeno-associated Virus Vectors Using Suspension HEK293 Cells and Continuous Harvest of Vector From the Culture Media for GMP FIX and FLT1 Clinical Vector. Mol Ther. 2015; 24(2):287-297. PMC: 4817810. DOI: 10.1038/mt.2015.187. View